Study of Pembrolizumab Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥50%

Trial Information
Eligibility
Locations
Next steps

Active, Not Recruiting

Trial Purpose

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).

View full trial information on Clinicaltrials.gov

	National Trial Reference Number	NCT05609968
	MSD Protocol ID	MK-3475-D46
	Conditions	Carcinoma, Non-Small-Cell Lung
	Age Range	18+
	Sex	ALL
	Trial Phase	3
	Start Date End Date	2023-02-06 2028-08-23

Study Details

Patient Participation

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial.

Conditions

Carcinoma, Non-Small-Cell Lung

View full trial eligibility

Trial Phase 3

In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.

View full trial information on Clinicaltrials.gov

Trial Locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

Sorry, there are no locations found.

What can you do next?

If you think this clinical trial might be a good fir and you are interested in taking part, take the next step to see if you are eligible.

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

Print Email

Contact our Trial Information Center

To learn more, call 1-888-577-8839

Taking part in a clinical trial is an important decision

If you are considering joining a clinical trial, first learn as much as you can about:

The investigational treatment that is being studied
What the risks and possible benefits are for participants

Talk to your doctor about the clinical trial before you decide to join.

Read our “What to Consider” page for more questions to ask and think about

Clinicaltrials.gov Identifier

NCT05609968

EudraCT Number

2022-000836-49

When you talk with your doctor or clinical trial team member, please have the trial identifier number or the EudraCT number available.